A carregar...
ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...
Na minha lista:
| Publicado no: | Neurooncol Adv |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7699102/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|